Anthropic has added Vas Narasimhan, chief executive of Novartis, to its board of directors, according to a Forbes report published April 19, 2026. Forbes frames the appointment as a signal that the AI company is deepening its commercial focus on healthcare. The same report states that Anthropic's Long-Term Benefit Trust (LTBT) has gained majority control over board governance.

What Forbes Reports

According to the Forbes article by John Werner, Narasimhan's addition to the board is being positioned by Anthropic as part of a broader healthcare strategy. Forbes characterizes the move as a signal of intent rather than an announcement of specific healthcare products or partnerships.

The Forbes report does not, in the material provided to DeepBrief, specify Narasimhan's full biographical details, the exact size of the Anthropic board after the appointment, or whether Narasimhan is taking a board seat previously held by another director. DeepBrief has not independently verified additional biographical claims about Narasimhan beyond his current role at Novartis as reported by Forbes.

The LTBT Governance Shift

Forbes also reports that Anthropic's Long-Term Benefit Trust has gained majority control over board governance. The LTBT is a structure Anthropic has previously described in its own public materials as a mechanism for steering the company toward its stated mission of safe AI development, with the authority to elect a portion of board directors.

Forbes frames the appointment as a signal that the AI company is deepening its commercial focus on healthcare.

The Forbes report does not, in the excerpt available to DeepBrief, detail the specific mechanics of how the LTBT's control threshold was crossed, whether this reflects a pre-planned governance milestone tied to Anthropic's founding documents, or a more recent structural change. Anthropic has, in past public statements, described the LTBT as being designed to take on expanded governance responsibilities over time.

Healthcare Context

Anthhropic has previously signaled interest in healthcare applications of its Claude model family through enterprise case studies and public statements, though the company has not, to DeepBrief's knowledge, announced a dedicated healthcare business unit. Narasimhan's appointment, as reported by Forbes, is a public indication of a board-level healthcare orientation at the company.

Novartis is one of the larger global pharmaceutical companies by revenue. Forbes reports that Narasimhan serves as its chief executive but does not, in the source material, provide additional details about his tenure or background that DeepBrief can attribute with confidence.

Anthropics enterprise customer base, per the company's own previous disclosures, includes firms across financial services, legal, software, and life sciences. The company has not publicly disclosed healthcare-specific revenue figures.

Competitive Backdrop

The healthcare AI market has drawn commercial attention from multiple frontier model developers. OpenAI has disclosed partnerships with healthcare providers and payers in its own announcements, and Google DeepMind has publicized medical research efforts through its research publications. Anthropic has been less publicly active in healthcare-specific marketing than several of its peers, based on publicly available company communications.

Forbes does not report specific healthcare products, partnerships, or revenue targets tied to Narasimhan's appointment. The article characterizes the move as directional rather than operational.

Outstanding Questions

DeepBrief has reached out to Anthropic for comment on the appointment and on the reported LTBT governance change. The following items remain unconfirmed by any source DeepBrief has reviewed:

  • The current total size of Anthropic's board and the exact number of LTBT-elected seats following the appointment.
  • Whether Narasimhan will retain his role as Novartis chief executive while serving on Anthropic's board, and any disclosed conflict-of-interest arrangements.
  • The specific trigger or timeline under which the LTBT reached majority board control, and whether this was pre-scheduled under Anthropic's founding governance structure.
  • Any commercial healthcare initiatives, partnerships, or product plans connected to the appointment.

Forbes's reporting is the sole source for the appointment and the governance shift as described in this article.